Clinical trial NCT03984799: Interleukin-5 Receptor Expression in COPD
Official title: Interleukin-5 Receptor Expression in COPD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COPD
Lead sponsor: University of Virginia
Sponsor class: OTHER
Collaborators: name: GlaxoSmithKline
First posted: 2019-06-13
Enrollment: 20
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: At visit one, after the subject has signed the consent form, subjects will answer questions and have maximum reversibility lung function test to determine if they are eligible to proceed with the study. Once the study team has proven that the subject is eligible to proceed the study team will collect a sputum sample and blood sample to study their cells. At visit two the subjects will undergo a research bronchoscopy at this point the study team will collect more samples including a BAL sample and another blood sample. Three follow up phone calls will be conducted after the procedure to ensure subject safety, the study team will record any symptoms that they are experiencing at that time. Throughout this study the samples will be analyzed to see if a larger subset of COPD patients could benefit from using the drug mepolizumab.

Detailed description: During this study the subjects will have a bronchoscopy where the study team will collect airway samples to see how the subjects express certain cells. The subjects will also have two blood draws to provide information on the number of inflammatory cells that are present in their blood. This will help the study team determine if mepolizumab might be able to be used in more patients with COPD. The use of mepolizumab in COPD subjects with elevated blood eosinophils has been proven effective. However, the cellular mechanisms in the COPD population are unknown, including the extent to which these subjects express IL-5 in their airway and whether eosinophils are the sole target. Through this study the study team plans to provide proof of concept that mepolizumab could target additional IL-5-expressing immune cells in the airway, including especially PMNs. The study team will also investigate additional feasible biomarkers that could be utilized to predict mepolizumab responsiveness in COPD. The study team is hoping to determine if COPD patients with elevated blood eosinophils will demonstrate increased concentrations of IL-5 in their bronchoalveolar lavage (BAL) fluid and increased expression in their BAL of CD125+ PMNs. To address this hypothesis, the following specific aims will be addressed: To define the expression of IL-5R on PMNs in COPD and to demonstrate elevated concentrations of IL-5 in BALF obtained from COPD subjects with blood eosinophils (≥300/µL).

Eligibility criteria: Inclusion Criteria:

* • Age ≥40 and ≤80.

  * COPD according to ATS-ERS guidelines
  * Current or former smokers (≥10 pack-years) / non-smokers without a history of asthma
  * FEV1/FVC ratio 0.70 before and after bronchodilator
  * FEV1 after bronchodilator ≥50% predicted and \<80% predicted
  * No recent exacerbation within 30 days of bronchoscopy
  * No symptoms of recent symptomatic infection (change in sputum volume or color in the previous 30 days).
  * Absolute eosinophil count \>300/µL within one month of the research bronchoscopy.

Exclusion Criteria:

* • Current diagnosis of asthma

  * Non-smokers with a history of asthma
  * Recent exacerbation within 30 days of bronchoscopy
  * Major medical co-morbid or primary disorder including systemic disorders involving the heart, CNS, renal, and endocrine systems
  * Positive pregnancy test at time of bronchoscopy in women of child-bearing years
  * Recent change in COPD control regimen (within 60 days). Stable orally-dosed CCS will not be a contraindication to study as long as the dose was not changed within 60 days.
  * Recent (with 1-year) administration of a biologic agent
  * Presence of allergic sensitization (atopy) (if obtained) will not be considered an exclusion.
  * Presence of hypereosinophil syndrome (HES), eosinophilic granulomatous polyangiitis (EGPA), nasal polyposis, helminth infection, or any other medical condition associated with eosinophilia

Primary outcomes:
measure: IL-5R expression on bronchial neutrophils
timeFrame: within 24 hours
measure: IL-5 concentration in BALF
timeFrame: within 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Charlottesville
country: United States
facility: University of Virginia
state: Virginia
Study officials:
References: